352 related articles for article (PubMed ID: 26198633)
1. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
2. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
3. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
4. Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses.
Klimosch SN; Bartel Y; Wiemann S; Steinle A
Blood; 2013 Oct; 122(14):2380-9. PubMed ID: 23929856
[TBL] [Abstract][Full Text] [Related]
5. Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.
Akatsuka A; Ito M; Yamauchi C; Ochiai A; Yamamoto K; Matsumoto N
Int Immunol; 2010 Sep; 22(9):783-90. PubMed ID: 20663776
[TBL] [Abstract][Full Text] [Related]
6. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
7. Peptide mimicry of AICL inhibits cytolysis of NK cells by blocking NKp80-AICL recognition.
Huang H; Zheng X; Tian Z; Sun R
Immunol Invest; 2010; 39(6):587-97. PubMed ID: 20653426
[TBL] [Abstract][Full Text] [Related]
8. NKp80 defines and stimulates a reactive subset of CD8 T cells.
Kuttruff S; Koch S; Kelp A; Pawelec G; Rammensee HG; Steinle A
Blood; 2009 Jan; 113(2):358-69. PubMed ID: 18922855
[TBL] [Abstract][Full Text] [Related]
9. Attenuated natural killer (NK) cell activation through C-type lectin-like receptor NKp80 is due to an anomalous hemi-immunoreceptor tyrosine-based activation motif (HemITAM) with impaired Syk kinase recruitment capacity.
Rückrich T; Steinle A
J Biol Chem; 2013 Jun; 288(24):17725-33. PubMed ID: 23609447
[TBL] [Abstract][Full Text] [Related]
10. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction.
Welte S; Kuttruff S; Waldhauer I; Steinle A
Nat Immunol; 2006 Dec; 7(12):1334-42. PubMed ID: 17057721
[TBL] [Abstract][Full Text] [Related]
11. Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.
Schmiedel BJ; Werner A; Steinbacher J; Nuebling T; Buechele C; Grosse-Hovest L; Salih HR
Mol Ther; 2013 Apr; 21(4):877-86. PubMed ID: 23380816
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
13. Cellular Mechanisms Controlling Surfacing of AICL Glycoproteins, Cognate Ligands of the Activating NK Receptor NKp80.
Neuss S; Bartel Y; Born C; Weil S; Koch J; Behrends C; Hoffmeister M; Steinle A
J Immunol; 2018 Aug; 201(4):1275-1286. PubMed ID: 29980609
[TBL] [Abstract][Full Text] [Related]
14. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.
Hu Z; Li J
BMC Immunol; 2010 Oct; 11():49. PubMed ID: 20939894
[TBL] [Abstract][Full Text] [Related]
16. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z
J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772
[TBL] [Abstract][Full Text] [Related]
17. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII-Fc Activates Natural Killer Cells
Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
Front Immunol; 2021; 12():692157. PubMed ID: 34262568
[TBL] [Abstract][Full Text] [Related]
19. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
[TBL] [Abstract][Full Text] [Related]
20. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
